Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review)
- Authors:
- Ranzhiqiang Yang
- Yinghui Song
- Kashif Shakoor
- Weimin Yi
- Chuang Peng
- Sulai Liu
-
Affiliations: Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005, P.R. China - Published online on: March 17, 2022 https://doi.org/10.3892/mmr.2022.12687
- Article Number: 171
-
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Razumilava N and Gores GJ: Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Saha SK, Zhu AX, Fuchs CS and Brooks GA: Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise. Oncologist. 21:594–599. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cucchetti A, Cappelli A, Mosconi C, Zhong JH, Cescon M, Pinna AD and Golfieri R: Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: A meta-regression study. Liver Int. 37:1056–1064. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang XW, Yuan JM, Chen JY, Yang J, Gao QG, Yan XZ, Zhang BH, Feng S and Wu MC: The prognostic importance of jaundice in surgical resection with curative intent for gallbladder cancer. BMC Cancer. 14:6522014. View Article : Google Scholar : PubMed/NCBI | |
|
Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER and Denlinger CS: Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 122:1349–1369. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ben-Menachem T: Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol. 19:615–617. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yang XW, Li L, Hou GJ, Yan XZ, Xu QG, Chen L, Zhang BH and Shen F: STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome. Oncotarget. 8:7710–7721. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Lee H, Herrmann A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Shen Y, Wang S, Shen Q and Zhou X: The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett. 415:117–128. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
To SQ, Dmello RS, Richards AK, Ernst M and Chand AL: STAT3 signaling in breast cancer: Multicellular actions and therapeutic potential. Cancers (Basel). 14:4292022. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Mohassab AM, Hassan HA, Abdelhamid D, Gouda AM, Youssif BGM, Tateishi H, Fujita M, Otsuka M and Abdel-Aziz M: STAT3 transcription factor as target for anti-cancer therapy. Pharmacol Rep. 72:1101–1124. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zimmers TA, Fishel ML and Bonetto A: STAT3 in the systemic inflammation of cancer cachexia. Semin Cell Dev Biol. 54:28–41. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Jin LL, Wybenga-Groot LE, Tong J, Taylor P, Minden MD, Trudel S, McGlade CJ and Moran MF: Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity. Mol Cell Proteomics. 14:695–706. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gutiérrez M: Activating mutations of STAT3: Impact on human growth. Mol Cell Endocrinol. 518:1109792020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang SW and Sun YM: The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol. 44:1032–1040. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Montero P, Milara J, Roger I and Cortijo J: Role of JAK/STAT in interstitial lung diseases; Molecular and cellular mechanisms. Int J Mol Sci. 22:62112021. View Article : Google Scholar : PubMed/NCBI | |
|
Banerjee S, Biehl A, Gadina M, Hasni S and Schwartz DM: JAK-STAT Signaling as a target for inflammatory and autoimmune diseases: Current and future prospects. Drugs. 77:521–546. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Ma H, Wei D and Sun S: The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 80:1062102020. View Article : Google Scholar : PubMed/NCBI | |
|
Yokoyama T, Komori A, Nakamura M, Takii Y, Kamihira T, Shimoda S, Mori T, Fujiwara S, Koyabu M, Taniguchi K, et al: Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int. 26:467–476. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bode JG, Ehlting C and Häussinger D: The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal. 24:1185–1194. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Z, Wang P, Sun R, Li J, Hu Z, Xin H, Luo C, Zhou J, Fan J and Zhou S: Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. J Immunother Cancer. 9:e0019462021. View Article : Google Scholar : PubMed/NCBI | |
|
Shaul ME and Fridlender ZG: Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 16:601–620. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tam WY and Chi H: Bipolar/rod-shaped microglia are proliferating microglia with distinct M1/M2 phenotypes. Sci Rep. 4:72792014. View Article : Google Scholar : PubMed/NCBI | |
|
Leticia P, Font-Nieves M, Van den Haute C, Baekelandt V, Planas AM and Pozas E: IL-10 regulates adult neurogenesis by modulating ERK and STAT3 activity. Front Cell Neurosci. 9:572015.PubMed/NCBI | |
|
Wu X, Pan T, Quan Z, Li J, Yu Z, Wang X, Li J, Li C, Yan M, Zhu Z, et al: IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget. 8:20741–20750. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ju JH, Heo YJ, Cho ML, Jhun JY, Park JS, Lee SY, Oh HJ, Moon SJ, Kwok SK, Park KS, et al: Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells. Arthritis Rheum. 64:3543–3552. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang XQ, Hu GH, Kou W, Shen Y, Kang HY and Hong SL: Reciprocal roles of STAT3 and STAT5 in nasal polyposis. Am J Otolaryngol. 33:741–752. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng Y, Wang Z, Deng L, Zhang G, Yuan X, Huang L, Xu W and Shen L: Modulation of STAT3 and STAT5 activity rectifies the imbalance of Th17 and Treg cells in patients with acute coronary syndrome. Clin Immunol. 157:65–77. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan H, Lin Z, Liu Y, Jiang Y, Liu K, Tu M, Yao N, Qu C and Hong J: Intrahepatic cholangiocarcinoma induced M2-polarized Tumor-associated macrophages facilitate tumor growth and invasiveness. Cancer Cell Int. 20:5862020. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Y, Chen J C, ZHU Z Y, et al: Research progress of EGFR gene mutation and its detection methods. Mol Diagn Ther. 3:51–57. 2011. | |
|
Roskoski R Jr: ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Pharmacol Res. 87:42–59. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bi WW, Zhang WH, Yin GH, Luo H, Wang SQ, Wang H, Li C, Yan WQ and Nie DZ: Analysis of indoleamine 2–3 dioxygenase (IDO) and EGFR co-expression in breast cancer tissue by immunohistochemistry. Asian Pac J Cancer Prev. 15:5535–5538. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao X, Sun X and Li XL: Expression and clinical significance of STAT3, p-STAT3, and VEGF-C in small cell lung cancer. Asian Pac J Cancer Prev. 13:2873–2877. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fang B: Genetic Interactions of STAT3 and Anticancer Drug Development. Cancers (Basel). 6:494–525. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S and DiGiovanni J: Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res. 64:2382–2389. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C, Xu H, Zhou Z, Tian Y, Cao X, Cheng G and Liu Q: Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. Exp Ther Med. 15:4995–5000. 2018.PubMed/NCBI | |
|
Zhang F, Li L, Yang X, Wang B, Zhao J, Lu S and Yu X: Expression and activation of EGFR and STAT3 during the multistage carcinogenesis of intrahepatic cholangiocarcinoma induced by 3′-methyl-4 dimethylaminoazobenzene in rats. J Toxicol Pathol. 28:79–87. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar KK, Burgess AW and Gulbis JM: Structure and function of LGR5: An enigmatic G-protein coupled receptor marking stem cells. Protein Sci. 23:551–565. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Katoh M: WNT signaling in stem cell biology and regenerative medicine. Curr Drug Targets. 9:565–570. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Katoh M and Katoh M: STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review). Int J Mol Med. 19:273–278. 2007.PubMed/NCBI | |
|
Katoh M and Katoh M: WNT signaling pathway and stem cell signaling network. Clin Cancer Res. 13:4042–4045. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gregorieff A and Clevers H: Wnt signaling in the intestinal epithelium: From endoderm to cancer. Genes Dev. 19:877–890. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kawasaki K, Kuboki S, Furukawa K, Takayashiki T, Takano S and Ohtsuka M: LGR5 induces β-catenin activation and augments tumour progression by activating STAT3 in human intrahepatic cholangiocarcinoma. Liver Int. 41:865–881. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chung KM, Hsu SC, Chu YR, Lin MY, Jiaang WT, Chen RH and Chen X: Fibroblast activation protein (FAP) is essential for the migration of bone marrow mesenchymal stem cells through RhoA activation. PLoS One. 9:e887722017. View Article : Google Scholar : PubMed/NCBI | |
|
Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ and Rettig WJ: Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 274:36505–36512. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Hamson EJ, Keane FM, Tholen S, Schilling O and Gorrell MD: Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 8:454–463. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Huber MA, Kraut N, Park JE, Schubert RD, Rettig WJ, Peter RU and Garin-Chesa P: Fibroblast activation protein: Differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol. 120:182–188. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W, Dang Y, Chu Y, Fan J and He R: FAP Promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 76:4124–4135. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, Mertens JC, Sirica AE and Gores GJ: Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 54:2076–2088. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ohira S, Sasaki M, Harada K, Sato Y, Zen Y, Isse K, Kozaka K, Ishikawa A, Oda K, Nimura Y and Nakanuma Y: Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1released in stroma. Am J Pathol. 168:1155–1168. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Claperon A, Mergey M, Aoudjehane L, Ho-Bouldoires TH, Wendum D, Prignon A, Merabtene F, Firrincieli D, Desbois-Mouthon C, Scatton O, et al: Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. Hepatology. 58:2001–2011. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Claperon A, Mergey M, Nguyen Ho-Bouldoires TH, Vignjevic D, Wendum D, Chrétien Y, Merabtene F, Frazao A, Paradis V, Housset C, et al: EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. J Hepatol. 61:325–332. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Y, Li B, Yang X, Cai Q, Liu W, Tian M, Luo H, Yin W, Song Y, Shi Y and He R: Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. Neoplasia. 21:1133–1142. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CL, Cen L, Kohout J, Hutzen B, Chan C, Hsieh FC, Loy A, Huang V, Cheng G and Lin J: Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 7:782008. View Article : Google Scholar : PubMed/NCBI | |
|
Sonnenblick A, Shriki A, Galun E, Axelrod JH, Daum H, Rottenberg Y, Hamburger T, Mali B and Peretz T: Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is amarker of good prognosis. Clin Transl Oncol. 14:232–236. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Schaefer LK, Ren Z, Fuller GN and Schaefer TS: Constitutive activation of Stat3alpha in brain tumors: Localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene. 21:2058–2065. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M, Kakuma T, et al: Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br J Cancer. 101:967–972. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang HF, Chen Y, Wu C, Wu ZY, Tweardy DJ, Alshareef A, Liao LD, Xue YJ, Wu JY, Chen B, et al: The opposing function of STAT3 as an oncoprotein and tumor suppressor is dictated by the expression status of STAT3β in esophageal squamous cell carcinoma. Clin Cancer Res. 22:691–703. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Geiger JL, Grandis JR and Bauman JE: The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 56:84–92. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Priceman SJ, Xin H, Zhang W, Deng J, Liu Y, Huang J, Zhu W, Chen M, Hu W, et al: Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS One. 8:e816572013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Qu A and Wang H: Signal transducer and activator of transcription 4 in liver diseases. Int J Biol Sci. 11:448–455. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Suh YA, Jo SY, Lee HY and Lee C: Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells. Int J Oncol. 46:1405–1411. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD and Jove R: Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 276:45443–45455. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD and Jove R: Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 3:261–269. 2004.PubMed/NCBI | |
|
Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, Kaluarachchi KK, Chen X, Bast RC Jr, Liao WS and McMurray JS: Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem. 54:3549–3563. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Auzenne EJ, Klostergaard J, Mandal PK, Liao WS, Lu Z, Gao F, Bast RC Jr, Robertson FM and McMurray JS: A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J Exp TherOncol. 10:155–162. 2012.PubMed/NCBI | |
|
Hayakawa F, Sugimoto K, Harada Y, Hashimoto N, Ohi N, Kurahashi S and Naoe T: A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J. 3:e1662013. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MJ, Nam HJ, Kim HP, Han SW, Im SA, Kim TY, Oh DY and Bang YJ: OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 335:145–152. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bendell JC, Hong DS, Burris HA III, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP and Kurzrock R: Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 74:125–130. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, Heo DS, Yuasa M, Yanagihara Y and Bang YJ: Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors. Cancer Res Treat. 47:607–615. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Okusaka T, Ueno H, Ikeda M, Mitsunaga S, Ozaka M, Ishii H, Yokosuka O, Ooka Y, Yoshimoto R, Yanagihara Y and Okita K: Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol Res. 45:1283–1291. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wong AL, Soo RA, Tan DS, Lee SC, Lim JS, Marban PC, Kong LR, Lee YJ, Wang LZ, Thuya WL, et al: Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 26:998–1005. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Taniwaki M, Takamatsu Y, Naoe T, Tobinai K, Munakata W, et al: Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Sci. 106:896–901. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bharadwaj U, Eckols TK, Xu X, Kasembeli MM, Chen Y, Adachi M, Song Y, Mo Q, Lai SY and Tweardy DJ: Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 7:26307–26330. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Xi S, Gooding WE and Grandis JR: In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: Implications for cancer therapy. Oncogene. 24:970–979. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shen J, Li R and Li G: Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo. In Vivo. 23:237–243. 2009.PubMed/NCBI | |
|
Sun Z, Yao Z, Liu S, Tang H and Yan X: An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology. 211:199–209. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Zhang J, Wang L, Wei H and Tian Z: Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer. 7:1492007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Liu P, Zhang B, Mao H, Shen L and Ma Y: Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo. Int J Mol Med. 32:623–628. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J and DiGiovanni J: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest. 114:720–728. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Hossain DM, Duttagupta P, Moreira D, Zhao X, Won H, Buettner R, Nechaev S, Majka M, Zhang B, et al: Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood. 127:1687–1700. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sun XJ, Jiang TH, Zhang XP and Mao AW: Role of the tumor microenvironment in pancreatic adenocarcinoma. Front Biosci (Landmark Ed). 21:31–41. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Eggert T and Greten TF: Tumor regulation of the tissue environment in the liver. Pharmacol Ther. 173:47–57. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Peng NF, Li LQ, Qin X, Guo Y, Peng T, Xiao KY, Chen XG, Yang YF, Su ZX, Chen B, et al: Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: A possible role of hepatitis B virus. Ann Surg Oncol. 18:1258–1266. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jarnicki A, Putoczki T and Ernst M: Stat3: Linking inflammation to epithelial cancer-more than a ‘gut’ feeling? Cell Div. 5:142010. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Liao S, Bennett S, Tang H, Song D, Wood D, Zhan X and Xu J: STAT3 and its targeting inhibitors in osteosarcoma. Cell Prolif. 54:e129742021. View Article : Google Scholar : PubMed/NCBI | |
|
Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M and Aggarwal BB: Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 103:3175–3184. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, et al: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Haura EB, Zheng Z, Song L, Cantor A and Bepler G: Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 11:8288–8294. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Ren Z, Shi Y, Guan C, Pan Z and Zong Z: Activation of signal transducers and activators of transcription 3 and overexpression of its target gene CyclinD1 in laryngeal carcinomas. Laryngoscope. 118:1976–1980. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bournazou E and Bromberg J: Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT. 2:e238282013.PubMed/NCBI | |
|
Yu H and Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidt-Arras D and Rose-John S: IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol. 64:1403–1415. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Zhang M, Li Y, Zhang Y and She Z: Effect of small interfering RNA targeting p63 on the proliferation and invasiveness of human cholangiocarcinoma cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 32:207–210. 2012.(In Chinese). PubMed/NCBI | |
|
Sia D, Tovar V, Moeini A and Llovet JM: Intrahepatic cholangiocarcinoma: Pathogenesis and rationale for molecular therapies. Oncogene. 32:4861–4870. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabró R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J, et al: Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 73:315–327. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Xiu P, Liu N, et al: Effects of STAT3 on proliferation and apoptosis of human intrahepatic bile duct carcinoma cells. Shandong Med J. 55:5–7. 2015.(In Chinese). | |
|
Dong J, Cheng XD, Zhang WD and Qin JJ: Recent update on development of Small-Molecule STAT3 inhibitors for cancer therapy: From phosphorylation inhibition to protein degradation. J Med Chem. 64:8884–8915. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Y, Tang Z, Yang J, Liu T and Tang Y: MicroRNA-7-5p Inhibits Migration, Invasion and Metastasis of Intrahepatic Cholangiocarcinoma by Inhibiting MyD88. J Clin Transl Hepatol. 9:809–817. 2021.PubMed/NCBI |
